Clinical Trial Update: Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating a monoclonal antibody therapy for leptomeningeal cancer has completed, providing early safety and tolerability data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Carcinomatosis

Drugs mentioned

• Monoclonal antibody therapy (unspecified)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Brain and Central Nervous System Tumors, Intraocular Melanoma | Phase 1 | Status: COMPLETED